Advertisement
Advertisement
DYAI
Dyadic International, Inc.
0.86
USDSponsored
+0.01
+1.72%
Mar 25, 15:56 UTC -4
Closed
After-Market
0.90
+0.04
+4.19%
DYAI Earnings Reports
Positive Surprise Ratio
DYAI beat 9 of 23 last estimates.
39%
Next Report
Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
$1.10M
/-$0.05
Implied change from Q4 25 (Revenue/ EPS)
+92.19%
/-16.67%
Implied change from Q1 25 (Revenue/ EPS)
+180.89%
/-28.57%
Dyadic International, Inc. earnings per share and revenue
On Mar 25, 2026, DYAI reported earnings of -0.06 USD per share (EPS) for Q4 25, missing the estimate of -0.04 USD, resulting in a -30.72% surprise. Revenue reached 570.00 thousand, compared to an expected 1.37 million, with a -58.41% difference.
Looking ahead to Q1 26, 3 analysts forecast an EPS of -0.05 USD, with revenue projected to reach 1.10 million USD, implying an decrease of -16.67% EPS, and increase of 92.19% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
FAQ
What were Dyadic International, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Dyadic International, Inc. reported EPS of -$0.06, missing estimates by -30.72%, and revenue of $570.00K, -58.41% below expectations.
How did the market react to Dyadic International, Inc.'s Q4 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Dyadic International, Inc. expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Dyadic International, Inc.'s next earnings report?
Based on 3
analysts, Dyadic International, Inc. is expected to report EPS of -$0.05 and revenue of $1.10M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement